Clinical Trial Update: Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years. [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated safety and immunogenicity of two FSME IMMUN NEW vaccinations in healthy children aged 1 to 6 years; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tick-borne Encephalitis

Drugs mentioned

• FSME IMMUN NEW (Tick-borne encephalitis vaccine (inactivated))

Snippet

Sponsor: Pfizer | Conditions: Tick-borne Encephalitis | Phase 2 | Status: COMPLETED